Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963262 | 1.00 | TBXAS1 (0.36) | TBXAS1RAPGEF4TGFBR1MKNK2CDC7 | |
| SCHEMBL964750 | 0.92 | MAPT (0.38) | TBXAS1RAPGEF4CDC7CDK2 | |
| SCHEMBL964752 | 0.92 | MAPT (0.38) | TBXAS1RAPGEF4CDC7CDK2 | |
| SCHEMBL963207 | 0.86 | PHGDH (0.36) | TBXAS1 | |
| SCHEMBL963205 | 0.86 | PHGDH (0.36) | TBXAS1 | |
| SCHEMBL962735 | 0.84 | ROCK1 (0.34) | RAPGEF4HSP90AA1 | |
| SCHEMBL962734 | 0.84 | ROCK1 (0.34) | RAPGEF4HSP90AA1 | |
| SCHEMBL966083 | 0.83 | MAPT (0.36) | — | |
| SCHEMBL966082 | 0.83 | MAPT (0.36) | — | |
| SCHEMBL964446 | 0.82 | CDC7 (0.34) | CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | TBXAS1 1574/4885RAPGEF4 952/4885TGFBR1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.